Loading the security page…
This security is no longer traded.
A security analysis is not yet prepared for this market.
The series is stated in the current share scale after splits; dividends are not included in the price
Kenvue is the consumer brand portfolio spun out of Johnson & Johnson: Tylenol, Listerine, Neutrogena, Band-Aid.
Everyday products from the pharmacy shelf are bought by habit and by name: a painkiller or a plaster is chosen without comparing formulations. That yields steady revenue and the ability to raise prices with inflation. Separating from pharmaceuticals was logical — the two businesses move at different speeds and carry different risks.
On separating, the company also inherited a share of the old problems: talc litigation remains part of the parent structure's legacy and continues to be argued in court. The second challenge is pressure from retailers' own labels, which offer the same active ingredient more cheaply. Kenvue pays a dividend.
Based on the last 12 months of reports, through 30 June 2026
The sector median covers every company in the sector on the US market, loss-making ones included.
Kenvue Inc. (KVUE) is a company in the Consumer defensive sector; its shares trade on NYSE.
The price of Kenvue Inc. (KVUE) on October 30, 2026 is 19.31 $, −1.28 % on the day. Over 52 weeks the stock traded between 14.02 $ and 20.13 $; the price now sits 87 % of the way up that range. Over the past year the price changed by +14.82 %. The P/E ratio is 22.61, which is close to the sector median (22.58). Market capitalization is 37.48 billion $, rank 3 among 12 stocks of the same industry with a known capitalization.
Kenvue Inc. trades on NYSE under the ticker KVUE. The company belongs to the Consumer defensive sector. The trading history on this page starts on 4 May 2023.
Over the past 52 weeks KVUE has traded between 14.02 $ and 20.13 $. As of 30 October 2026 the price stood 76.10 % of the way from the 52-week low to the high.
Over one year KVUE shares rose 14.82 %; over six months they rose 6.93 %. Volatility over 90 days is 21.64 %. Dividends are not included: this is price change only, as of 30 October 2026.
KVUE trades at a price-to-earnings ratio of 22.6, above the sector median of 22.6. Price to sales is 2.4, above the sector median of 0.8. Price to book is 3.6, above the sector median of 2.0. Calculated from reports for the period ending 30 June 2026.
Kenvue Inc. reported revenue of 15.4B $ and net income of 1.7B $ over the last four quarters. Net margin is 10.76 %. Revenue changed by +1.76 % year over year. Earnings per share are 0.85 $. Market capitalisation is 37.5B $.
KVUE has a return on equity of 15.71 %, above the sector median of 6.34 %. Return on assets is 6.20 %, above the sector median of 2.28 %. Operating margin is 17.07 %, above the sector median of 3.54 %.